spacer
spacer
Go to PDB code: 
protein dna_rna metals Protein-protein interface(s) links
Antitumor protein/DNA PDB id
1tsr
Jmol
Contents
Protein chains
196 a.a. *
DNA/RNA
Metals
_ZN ×3
Waters ×384
* Residue conservation analysis
PDB id:
1tsr
Name: Antitumor protein/DNA
Title: P53 core domain in complex with DNA
Structure: DNA (5'- d( Tp Tp Tp Cp Cp Tp Ap Gp Ap Cp Tp Tp Gp Cp Cp Cp A p Ap Tp Tp A)-3'). Chain: e. Engineered: yes. DNA (5'- d( Ap Tp Ap Ap Tp Tp Gp Gp Gp Cp Ap Ap Gp Tp Cp Tp A p Gp Gp Ap A)-3'). Chain: f.
Source: Synthetic: yes. Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562.
Biol. unit: Trimer (from PQS)
Resolution:
2.20Å     R-factor:   0.205    
Authors: Y.Cho,S.Gorina,P.Jeffrey,N.Pavletich
Key ref: Y.Cho et al. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science, 265, 346-355. PubMed id: 8023157 DOI: 10.1126/science.8023157
Date:
28-Jul-95     Release date:   29-Jan-96    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
P04637  (P53_HUMAN) -  Cellular tumor antigen p53
Seq:
Struc:
393 a.a.
196 a.a.
Key:    PfamA domain  Secondary structure  CATH domain

 Gene Ontology (GO) functional annotation 
  GO annot!
  Cellular component     nucleus   1 term 
  Biological process     apoptosis   2 terms 
  Biochemical function     transcription regulatory region DNA binding     3 terms  

 

 
DOI no: 10.1126/science.8023157 Science 265:346-355 (1994)
PubMed id: 8023157  
 
 
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
Y.Cho, S.Gorina, P.D.Jeffrey, N.P.Pavletich.
 
  ABSTRACT  
 
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
 

Literature references that cite this PDB file's key reference

  PubMed id Reference
20818437 A.S.Azmi, P.A.Philip, F.W.Beck, Z.Wang, S.Banerjee, S.Wang, D.Yang, F.H.Sarkar, and R.M.Mohammad (2011).
MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy.
  Oncogene, 30, 117-126.  
21464285 C.Chen, N.Gorlatova, Z.Kelman, and O.Herzberg (2011).
Structures of p63 DNA binding domain in complexes with half-site and with spacer-containing full response elements.
  Proc Natl Acad Sci U S A, 108, 6456-6461.
PDB codes: 3qym 3qyn
21208455 F.Cui, M.V.Sirotin, and V.B.Zhurkin (2011).
Impact of Alu repeats on the evolution of human p53 binding sites.
  Biol Direct, 6, 2.  
21184255 G.Li, R.Wang, J.Gao, K.Deng, J.Wei, and Y.Wei (2011).
RNA interference-mediated silencing of iASPP induces cell proliferation inhibition and G0/G1 cell cycle arrest in U251 human glioblastoma cells.
  Mol Cell Biochem, 350, 193-200.  
21071400 I.Beno, K.Rosenthal, M.Levitine, L.Shaulov, and T.E.Haran (2011).
Sequence-dependent cooperative binding of p53 to DNA targets and its relationship to the structural properties of the DNA targets.
  Nucleic Acids Res, 39, 1919-1932.  
21177650 J.F.Millau, O.J.Bandele, J.Perron, N.Bastien, E.F.Bouchard, L.Gaudreau, D.A.Bell, and R.Drouin (2011).
Formation of stress-specific p53 binding patterns is influenced by chromatin but not by modulation of p53 binding affinity to response elements.
  Nucleic Acids Res, 39, 3053-3063.  
21472523 J.Scotcher, D.J.Clarke, S.K.Weidt, C.L.Mackay, T.R.Hupp, P.J.Sadler, and P.R.Langridge-Smith (2011).
Identification of Two Reactive Cysteine Residues in the Tumor Suppressor Protein p53 Using Top-Down FTICR Mass Spectrometry.
  J Am Soc Mass Spectrom, 22, 888-897.  
21338609 N.Khazanov, and Y.Levy (2011).
Sliding of p53 along DNA can be modulated by its oligomeric state and by cross-talks between its constituent domains.
  J Mol Biol, 408, 335-355.  
21263025 P.A.Muller, K.H.Vousden, and J.C.Norman (2011).
p53 and its mutants in tumor cell migration and invasion.
  J Cell Biol, 192, 209-218.  
21178074 R.Melero, S.Rajagopalan, M.Lázaro, A.C.Joerger, T.Brandt, D.B.Veprintsev, G.Lasso, D.Gil, S.H.Scheres, J.M.Carazo, A.R.Fersht, and M.Valle (2011).
Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA.
  Proc Natl Acad Sci U S A, 108, 557-562.  
21323968 R.Santi, V.Cetica, A.Franchi, M.Pepi, A.M.Cesinaro, C.Miracco, M.Paglierani, V.De Giorgi, C.Delfino, E.M.Difonzo, N.Pimpinelli, S.Bianchi, I.Sardi, M.Santucci, and D.Massi (2011).
Tumour suppressor gene TP53 mutations in atypical vascular lesions of breast skin following radiotherapy.
  Histopathology, 58, 455-466.  
21522129 T.J.Petty, S.Emamzadah, L.Costantino, I.Petkova, E.S.Stavridi, J.G.Saven, E.Vauthey, and T.D.Halazonetis (2011).
An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity.
  EMBO J, 30, 2167-2176.
PDB codes: 3q01 3q05 3q06
21076775 T.Wang, X.Shao, W.Cai, Y.Xue, S.Wang, and X.Feng (2011).
Predicting the coordination geometry for Mg2+ in the p53 DNA-binding domain: insights from computational studies.
  Phys Chem Chem Phys, 13, 1140-1151.  
  20516128 A.C.Joerger, and A.R.Fersht (2010).
The tumor suppressor p53: from structures to drug discovery.
  Cold Spring Harb Perspect Biol, 2, a000919.  
20113312 A.Merabet, H.Houlleberghs, K.Maclagan, E.Akanho, T.T.Bui, B.Pagano, A.F.Drake, F.Fraternali, and P.V.Nikolova (2010).
Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights.
  Biochem J, 427, 225-236.  
19933157 A.P.Bom, M.S.Freitas, F.S.Moreira, D.Ferraz, D.Sanches, A.M.Gomes, A.P.Valente, Y.Cordeiro, and J.L.Silva (2010).
The p53 core domain is a molten globule at low pH: functional implications of a partially unfolded structure.
  J Biol Chem, 285, 2857-2866.  
20662002 B.Doyle, J.P.Morton, D.W.Delaney, R.A.Ridgway, J.A.Wilkins, and O.J.Sansom (2010).
p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma.
  J Pathol, 222, 129-137.  
  20100603 B.Xue, R.L.Dunbrack, R.W.Williams, A.K.Dunker, and V.N.Uversky (2010).
PONDR-FIT: a meta-predictor of intrinsically disordered amino acids.
  Biochim Biophys Acta, 1804, 996.  
20696896 D.Coutandin, H.D.Ou, F.Löhr, and V.Dötsch (2010).
Tracing the protectors path from the germ line to the genome.
  Proc Natl Acad Sci U S A, 107, 15318-15325.  
20208557 D.H.Kim, E.H.Kim, H.K.Na, Y.Sun, and Y.J.Surh (2010).
15-Deoxy-Delta(12,14)-prostaglandin J(2) stabilizes, but functionally inactivates p53 by binding to the cysteine 277 residue.
  Oncogene, 29, 2560-2576.  
20808887 E.N.Kouwenhoven, S.J.van Heeringen, J.J.Tena, M.Oti, B.E.Dutilh, M.E.Alonso, E.de la Calle-Mustienes, L.Smeenk, T.Rinne, L.Parsaulian, E.Bolat, R.Jurgelenaite, M.A.Huynen, A.Hoischen, J.A.Veltman, H.G.Brunner, T.Roscioli, E.Oates, M.Wilson, M.Manzanares, J.L.Gómez-Skarmeta, H.G.Stunnenberg, M.Lohrum, H.van Bokhoven, and H.Zhou (2010).
Genome-wide profiling of p63 DNA-binding sites identifies an element that regulates gene expression during limb development in the 7q21 SHFM1 locus.
  PLoS Genet, 6, e1001065.  
19887449 G.Sahu, D.Wang, C.B.Chen, V.B.Zhurkin, R.E.Harrington, E.Appella, G.L.Hager, and A.K.Nagaich (2010).
p53 binding to nucleosomal DNA depends on the rotational positioning of DNA response element.
  J Biol Chem, 285, 1321-1332.  
20421238 H.Ide, Y.Terado, S.Tokiwa, K.Nishio, K.Saito, S.Isotani, Y.Kamiyama, S.Muto, T.Imamura, and S.Horie (2010).
Novel germ line mutation p53-P177R in adult adrenocortical carcinoma producing neuron-specific enolase as a possible marker.
  Jpn J Clin Oncol, 40, 815-818.  
19846609 J.Binkley, K.Karra, A.Kirby, M.Hosobuchi, E.A.Stone, and A.Sidow (2010).
ProPhylER: a curated online resource for protein function and structure based on evolutionary constraint analyses.
  Genome Res, 20, 142-154.  
21142860 J.D.Martinez (2010).
Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy.
  Future Oncol, 6, 1857-1862.  
20553493 J.E.Kucab, D.H.Phillips, and V.M.Arlt (2010).
Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model.
  FEBS J, 277, 2567-2583.  
20407015 J.J.Jordan, A.Inga, K.Conway, S.Edmiston, L.A.Carey, L.Wu, and M.A.Resnick (2010).
Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.
  Mol Cancer Res, 8, 701-716.  
20393595 J.K.Eibl, Z.Abdallah, and G.M.Ross (2010).
Zinc-metallothionein: a potential mediator of antioxidant defence mechanisms in response to dopamine-induced stress.
  Can J Physiol Pharmacol, 88, 305-312.  
21159183 J.K.Peltonen, H.M.Helppi, P.Pääkkö, T.Turpeenniemi-Hujanen, and K.H.Vähäkangas (2010).
p53 in head and neck cancer: functional consequences and environmental implications of TP53 mutations.
  Head Neck Oncol, 2, 36.  
20128691 J.Malcikova, B.Tichy, J.Damborsky, J.Kabathova, M.Trbusek, J.Mayer, and S.Pospisilova (2010).
Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation.
  Biol Chem, 391, 197-205.  
20446770 J.Shlomai (2010).
Redox control of protein-DNA interactions: from molecular mechanisms to significance in signal transduction, gene expression, and DNA replication.
  Antioxid Redox Signal, 13, 1429-1476.  
20498645 K.G.Wiman (2010).
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
  Oncogene, 29, 4245-4252.  
20364130 M.Kitayner, H.Rozenberg, R.Rohs, O.Suad, D.Rabinovich, B.Honig, and Z.Shakked (2010).
Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs.
  Nat Struct Mol Biol, 17, 423-429.
PDB codes: 3igk 3igl 3kz8
20432164 M.L.Slattery, R.K.Wolff, J.S.Herrick, B.J.Caan, and W.Samowitz (2010).
Calcium, vitamin D, VDR genotypes, and epigenetic and genetic changes in rectal tumors.
  Nutr Cancer, 62, 436-442.  
20628283 M.L.Slattery, R.K.Wolff, J.S.Herrick, K.Curtin, B.J.Caan, and W.Samowitz (2010).
Alcohol consumption and rectal tumor mutations and epigenetic changes.
  Dis Colon Rectum, 53, 1182-1189.  
20062013 M.Liang, X.Han, S.Vadhan-Raj, M.Nguyen, Y.H.Zhang, M.Fernandez, E.Drakos, S.N.Konoplev, C.C.Yin, R.N.Miranda, T.J.McDonnell, L.J.Medeiros, and C.E.Bueso-Ramos (2010).
HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis.
  Mod Pathol, 23, 381-391.  
  20182602 M.Olivier, M.Hollstein, and P.Hainaut (2010).
TP53 mutations in human cancers: origins, consequences, and clinical use.
  Cold Spring Harb Perspect Biol, 2, a001008.  
20639885 M.V.Poyurovsky, C.Katz, O.Laptenko, R.Beckerman, M.Lokshin, J.Ahn, I.J.Byeon, R.Gabizon, M.Mattia, A.Zupnick, L.M.Brown, A.Friedler, and C.Prives (2010).
The C terminus of p53 binds the N-terminal domain of MDM2.
  Nat Struct Mol Biol, 17, 982-989.  
20581117 R.Baronio, S.A.Danziger, L.V.Hall, K.Salmon, G.W.Hatfield, R.H.Lathrop, and P.Kaiser (2010).
All-codon scanning identifies p53 cancer rescue mutations.
  Nucleic Acids Res, 38, 7079-7088.  
20589832 R.E.Perez, C.D.Knights, G.Sahu, J.Catania, V.K.Kolukula, D.Stoler, A.Graessmann, V.Ogryzko, M.Pishvaian, C.Albanese, and M.L.Avantaggiati (2010).
Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.
  J Cell Physiol, 225, 394-405.  
20514025 R.Puca, L.Nardinocchi, D.Givol, and G.D'Orazi (2010).
Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.
  Oncogene, 29, 4378-4387.  
20334529 R.Rohs, X.Jin, S.M.West, R.Joshi, B.Honig, and R.S.Mann (2010).
Origins of specificity in protein-DNA recognition.
  Annu Rev Biochem, 79, 233-269.  
20368720 S.Chitayat, and C.H.Arrowsmith (2010).
Four p(53)s in a pod.
  Nat Struct Mol Biol, 17, 390-391.  
20190805 V.Marcel, V.Vijayakumar, L.Fernández-Cuesta, H.Hafsi, C.Sagne, A.Hautefeuille, M.Olivier, and P.Hainaut (2010).
p53 regulates the transcription of its Delta133p53 isoform through specific response elements contained within the TP53 P2 internal promoter.
  Oncogene, 29, 2691-2700.  
20843368 X.Zhang, Q.Zhang, J.Zhang, L.Qiu, S.S.Yan, J.Feng, Y.Sun, X.Huang, K.H.Lu, and Z.Li (2010).
FATS is a transcriptional target of p53 and associated with antitumor activity.
  Mol Cancer, 9, 244.  
20159469 Y.Chen, R.Dey, and L.Chen (2010).
Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer.
  Structure, 18, 246-256.
PDB code: 3kmd
  20700496 Y.Pan, and R.Nussinov (2010).
Lysine120 interactions with p53 response elements can allosterically direct p53 organization.
  PLoS Comput Biol, 6, 0.  
19776744 A.J.Levine, and M.Oren (2009).
The first 30 years of p53: growing ever more complex.
  Nat Rev Cancer, 9, 749-758.  
19286366 A.L.Okorokov, and E.V.Orlova (2009).
Structural biology of the p53 tumour suppressor.
  Curr Opin Struct Biol, 19, 197-202.  
  19384014 A.Pelit, N.Bal, Y.A.Akova, and B.Demirhan (2009).
p53 expression in pterygium in two climatic regions in Turkey.
  Indian J Ophthalmol, 57, 203-206.  
19794270 A.S.Sameer, S.ul Rehman, A.A.Pandith, N.Syeed, Z.A.Shah, N.A.Chowdhri, K.A.Wani, and M.A.Siddiqi (2009).
Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area.
  Saudi J Gastroenterol, 15, 244-252.  
19224335 B.De Felice, C.Garbi, M.Santoriello, A.Santillo, and R.R.Wilson (2009).
Differential apoptosis markers in human keloids and hypertrophic scars fibroblasts.
  Mol Cell Biochem, 327, 191-201.  
19208646 B.H.Cai, J.Y.Chen, M.H.Lu, L.T.Chang, H.C.Lin, Y.M.Chang, and C.F.Chao (2009).
Functional four-base A/T gap core sequence CATTAG of P53 response elements specifically bound tetrameric P53 differently than two-base A/T gap core sequence CATG bound both dimeric and tetrameric P53.
  Nucleic Acids Res, 37, 1984-1990.  
19681600 C.S.Stoner, G.D.Pearson, A.Koç, J.R.Merwin, N.I.Lopez, and G.F.Merrill (2009).
Effect of thioredoxin deletion and p53 cysteine replacement on human p53 activity in wild-type and thioredoxin reductase null yeast.
  Biochemistry, 48, 9156-9169.  
19749793 D.Walerych, M.B.Olszewski, M.Gutkowska, A.Helwak, M.Zylicz, and A.Zylicz (2009).
Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions.
  Oncogene, 28, 4284-4294.  
19736307 E.Gallardo, A.Navarro, N.Viñolas, R.M.Marrades, T.Diaz, B.Gel, A.Quera, E.Bandres, J.Garcia-Foncillas, J.Ramirez, and M.Monzo (2009).
miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.
  Carcinogenesis, 30, 1903-1909.  
19672623 E.Solcia, C.Klersy, L.Mastracci, P.Alberizzi, M.E.Candusso, M.Diegoli, F.Tava, R.Riboni, R.Manca, and O.Luinetti (2009).
A combined histologic and molecular approach identifies three groups of gastric cancer with different prognosis.
  Virchows Arch, 455, 197-211.  
19933326 F.Huang, S.Rajagopalan, G.Settanni, R.J.Marsh, D.A.Armoogum, N.Nicolaou, A.J.Bain, E.Lerner, E.Haas, L.Ying, and A.R.Fersht (2009).
Multiple conformations of full-length p53 detected with single-molecule fluorescence resonance energy transfer.
  Proc Natl Acad Sci U S A, 106, 20758-20763.  
19364824 H.C.Kim, and J.M.Huibregtse (2009).
Polyubiquitination by HECT E3s and the determinants of chain type specificity.
  Mol Cell Biol, 29, 3307-3318.  
  19462533 J.Ahn, M.V.Poyurovsky, N.Baptiste, R.Beckerman, C.Cain, M.Mattia, K.McKinney, J.Zhou, A.Zupnick, V.Gottifredi, and C.Prives (2009).
Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein.
  Cell Cycle, 8, 1603-1615.  
19558493 J.Carlsson, T.Soussi, and B.Persson (2009).
Investigation and prediction of the severity of p53 mutants using parameters from structural calculations.
  FEBS J, 276, 4142-4155.  
19533719 J.L.Goodman, D.B.Fried, and A.Schepartz (2009).
Bipartite tetracysteine display requires site flexibility for ReAsH coordination.
  Chembiochem, 10, 1644-1647.  
19411067 J.M.Lambert, P.Gorzov, D.B.Veprintsev, M.Söderqvist, D.Segerbäck, J.Bergman, A.R.Fersht, P.Hainaut, K.G.Wiman, and V.J.Bykov (2009).
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.
  Cancer Cell, 15, 376-388.  
18978813 K.A.Malecka, W.C.Ho, and R.Marmorstein (2009).
Crystal structure of a p53 core tetramer bound to DNA.
  Oncogene, 28, 325-333.
PDB codes: 3exj 3exl
20017945 L.Taja-Chayeb, S.Vidal-Millán, O.Gutiérrez-Hernández, C.Trejo-Becerril, E.Pérez-Cárdenas, A.Chávez-Blanco, E.de la Cruz-Hernández, and A.Dueñas-González (2009).
Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome.
  World J Surg Oncol, 7, 97.  
19519454 M.Miller (2009).
The importance of being flexible: the case of basic region leucine zipper transcriptional regulators.
  Curr Protein Pept Sci, 10, 244-269.  
18976161 M.Muller (2009).
Cellular senescence: molecular mechanisms, in vivo significance, and redox considerations.
  Antioxid Redox Signal, 11, 59-98.  
18297428 M.Wasielewski, P.Hanifi-Moghaddam, A.Hollestelle, S.D.Merajver, A.van den Ouweland, J.G.Klijn, S.P.Ethier, and M.Schutte (2009).
Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines.
  Breast Cancer Res Treat, 113, 285-291.  
20064378 P.A.Muller, P.T.Caswell, B.Doyle, M.P.Iwanicki, E.H.Tan, S.Karim, N.Lukashchuk, D.A.Gillespie, R.L.Ludwig, P.Gosselin, A.Cromer, J.S.Brugge, O.J.Sansom, J.C.Norman, and K.H.Vousden (2009).
Mutant p53 drives invasion by promoting integrin recycling.
  Cell, 139, 1327-1341.  
19717093 P.Hainaut, and K.G.Wiman (2009).
30 years and a long way into p53 research.
  Lancet Oncol, 10, 913-919.  
19386914 Q.Qin, M.Baudry, G.Liao, A.Noniyev, J.Galeano, and X.Bi (2009).
A novel function for p53: regulation of growth cone motility through interaction with Rho kinase.
  J Neurosci, 29, 5183-5192.  
19756158 S.A.Danziger, R.Baronio, L.Ho, L.Hall, K.Salmon, G.W.Hatfield, P.Kaiser, and R.H.Lathrop (2009).
Predicting positive p53 cancer rescue regions using Most Informative Positive (MIP) active learning.
  PLoS Comput Biol, 5, e1000498.  
19690369 S.Emamzadah, T.J.Petty, V.De Almeida, T.Nishimura, J.Joly, J.L.Ferrer, and T.D.Halazonetis (2009).
Cyclic olefin homopolymer-based microfluidics for protein crystallization and in situ X-ray diffraction.
  Acta Crystallogr D Biol Crystallogr, 65, 913-920.  
19494119 S.M.Sykes, T.J.Stanek, A.Frank, M.E.Murphy, and S.B.McMahon (2009).
Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53.
  J Biol Chem, 284, 20197-20205.  
19195024 S.Ogane, T.Onda, N.Takano, T.Yajima, T.Uchiyama, and T.Shibahara (2009).
Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma.
  Int J Cancer, 124, 2651-2657.  
20030809 T.Brandt, M.Petrovich, A.C.Joerger, and D.B.Veprintsev (2009).
Conservation of DNA-binding specificity and oligomerisation properties within the p53 family.
  BMC Genomics, 10, 628.  
  19925028 U.Chandrachud, and S.Gal (2009).
Three assays show differences in binding of wild-type and mutant p53 to unique gene sequences.
  Technol Cancer Res Treat, 8, 445-453.  
19440353 W.Duan, L.Gao, X.Wu, E.M.Hade, J.X.Gao, H.Ding, S.H.Barsky, G.A.Otterson, and M.A.Villalona-Calero (2009).
Expression of a Mutant p53 Results in an Age-Related Demographic Shift in Spontaneous Lung Tumor Formation in Transgenic Mice.
  PLoS ONE, 4, e5563.  
19072763 W.Gao, H.H.Mady, M.F.Melhem, and P.Keohavong (2009).
Analysis of p53 mutations in histologically normal lung tissues and lung tumors from non-small cell lung cancer patients.
  Mol Carcinog, 48, 633-641.  
19748724 Y.H.Tan, Y.M.Chen, X.Ye, Q.Lu, V.Tretyachenko-Ladokhina, W.Yang, D.F.Senear, and R.Luo (2009).
Molecular mechanisms of functional rescue mediated by P53 tumor suppressor mutations.
  Biophys Chem, 145, 37-44.  
19629163 Y.Pan, and R.Nussinov (2009).
Cooperativity dominates the genomic organization of p53-response elements: a mechanistic view.
  PLoS Comput Biol, 5, e1000448.  
19477430 Y.Wang, J.Yang, H.Zheng, G.J.Tomasek, P.Zhang, P.E.McKeever, E.Y.Lee, and Y.Zhu (2009).
Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model.
  Cancer Cell, 15, 514-526.  
19297420 Y.Xue, S.Wang, and X.Feng (2009).
Influence of magnesium ion on the binding of p53 DNA-binding domain to DNA-response elements.
  J Biochem, 146, 77-85.  
19346293 Y.Xue, S.Wang, and X.Feng (2009).
Effect of metal ion on the structural stability of tumour suppressor protein p53 DNA-binding domain.
  J Biochem, 146, 193-200.  
  19434769 Y.Zhao, X.Q.Chen, and J.Z.Du (2009).
Cellular adaptation to hypoxia and p53 transcription regulation.
  J Zhejiang Univ Sci B, 10, 404-410.  
18410249 A.C.Joerger, and A.R.Fersht (2008).
Structural biology of the tumor suppressor p53.
  Annu Rev Biochem, 77, 557-582.  
18579587 A.Kumar, W.S.Joo, G.Meinke, S.Moine, E.N.Naumova, and P.A.Bullock (2008).
Evidence for a structural relationship between BRCT domains and the helicase domains of the replication initiators encoded by the Polyomaviridae and Papillomaviridae families of DNA tumor viruses.
  J Virol, 82, 8849-8862.  
18315848 A.Madhumalar, D.J.Smith, and C.Verma (2008).
Stability of the core domain of p53: insights from computer simulations.
  BMC Bioinformatics, 9, S17.  
18275858 B.Liu, Y.Chen, and D.K.St Clair (2008).
ROS and p53: a versatile partnership.
  Free Radic Biol Med, 44, 1529-1535.  
18366598 C.J.Oldfield, J.Meng, J.Y.Yang, M.Q.Yang, V.N.Uversky, and A.K.Dunker (2008).
Flexible nets: disorder and induced fit in the associations of p53 and 14-3-3 with their partners.
  BMC Genomics, 9, S1.  
18453682 C.Tu, Y.H.Tan, G.Shaw, Z.Zhou, Y.Bai, R.Luo, and X.Ji (2008).
Impact of low-frequency hotspot mutation R282Q on the structure of p53 DNA-binding domain as revealed by crystallography at 1.54 angstroms resolution.
  Acta Crystallogr D Biol Crystallogr, 64, 471-477.
PDB code: 2pcx
17972286 D.F.Lowry, A.Stancik, R.M.Shrestha, and G.W.Daughdrill (2008).
Modeling the accessible conformations of the intrinsically unstructured transactivation domain of p53.
  Proteins, 71, 587-598.  
17724467 D.Grochova, J.Vankova, J.Damborsky, B.Ravcukova, J.Smarda, B.Vojtesek, and J.Smardova (2008).
Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast.
  Oncogene, 27, 1243-1252.  
18524770 E.C.Pietsch, E.Perchiniak, A.A.Canutescu, G.Wang, R.L.Dunbrack, and M.E.Murphy (2008).
Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.
  J Biol Chem, 283, 21294-21304.  
18314014 E.J.Merino, A.K.Boal, and J.K.Barton (2008).
Biological contexts for DNA charge transport chemistry.
  Curr Opin Chem Biol, 12, 229-237.  
17876829 E.Kwon, D.Y.Kim, S.W.Suh, and K.K.Kim (2008).
Crystal structure of the mouse p53 core domain in zinc-free state.
  Proteins, 70, 280-283.
PDB code: 2p52
18494939 G.Cenini, R.Sultana, M.Memo, and D.A.Butterfield (2008).
Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease.
  J Cell Mol Med, 12, 987-994.  
18095870 H.Donninger, A.Binder, L.Bohm, and M.I.Parker (2008).
Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells.
  Biol Chem, 389, 57-67.  
18048389 H.Shi, J.M.Lambert, A.Hautefeuille, V.J.Bykov, K.G.Wiman, P.Hainaut, and C.C.de Fromentel (2008).
In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249.
  Carcinogenesis, 29, 1428-1434.  
17983740 H.Zhang, X.Yang, K.Wang, W.Tan, H.Li, X.Zuo, and J.Wen (2008).
On-chip oligonucleotide ligation assay using one-dimensional microfluidic beads array for the detection of low-abundant DNA point mutations.
  Biosens Bioelectron, 23, 945-951.  
18495754 I.G.Lyakhov, A.Krishnamachari, and T.D.Schneider (2008).
Discovery of novel tumor suppressor p53 response elements using information theory.
  Nucleic Acids Res, 36, 3828-3833.  
17972073 J.P.Huidobro-Toro, R.A.Lorca, and C.Coddou (2008).
Trace metals in the brain: allosteric modulators of ligand-gated receptor channels, the case of ATP-gated P2X receptors.
  Eur Biophys J, 37, 301-314.  
17684488 K.C.Lee, W.L.Goh, M.Xu, N.Kua, D.Lunny, J.S.Wong, D.Coomber, B.Vojtesek, E.B.Lane, and D.P.Lane (2008).
Detection of the p53 response in zebrafish embryos using new monoclonal antibodies.
  Oncogene, 27, 629-640.  
18559976 K.H.Young, K.Leroy, M.B.Møller, G.W.Colleoni, M.Sánchez-Beato, F.R.Kerbauy, C.Haioun, J.C.Eickhoff, A.H.Young, P.Gaulard, M.A.Piris, T.D.Oberley, W.M.Rehrauer, B.S.Kahl, J.S.Malter, E.Campo, J.Delabie, R.D.Gascoyne, A.Rosenwald, L.Rimsza, J.Huang, R.M.Braziel, E.S.Jaffe, W.H.Wilson, L.M.Staudt, J.M.Vose, W.C.Chan, D.D.Weisenburger, and T.C.Greiner (2008).
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.
  Blood, 112, 3088-3098.  
18922183 L.Vrba, D.J.Junk, P.Novak, and B.W.Futscher (2008).
p53 induces distinct epigenetic states at its direct target promoters.
  BMC Genomics, 9, 486.  
18515839 M.Gao, and J.Skolnick (2008).
DBD-Hunter: a knowledge-based method for the prediction of DNA-protein interactions.
  Nucleic Acids Res, 36, 3978-3992.  
18621913 M.M.García-Alai, H.Tidow, E.Natan, F.M.Townsley, D.B.Veprintsev, and A.R.Fersht (2008).
The novel p53 isoform "delta p53" is a misfolded protein and does not bind the p21 promoter site.
  Protein Sci, 17, 1671-1678.  
18391200 M.Wells, H.Tidow, T.J.Rutherford, P.Markwick, M.R.Jensen, E.Mylonas, D.I.Svergun, M.Blackledge, and A.R.Fersht (2008).
Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain.
  Proc Natl Acad Sci U S A, 105, 5762-5767.  
18275817 R.A.Robinson, X.Lu, E.Y.Jones, and C.Siebold (2008).
Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73.
  Structure, 16, 259-268.
PDB code: 2vge
18725978 R.Chrisanthar, S.Knappskog, E.Løkkevik, G.Anker, B.Østenstad, S.Lundgren, E.O.Berge, T.Risberg, I.Mjaaland, L.Maehle, L.F.Engebretsen, J.R.Lillehaug, and P.E.Lønning (2008).
CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
  PLoS ONE, 3, e3062.  
18216867 R.E.Tiedemann, N.Gonzalez-Paz, R.A.Kyle, R.Santana-Davila, T.Price-Troska, S.A.Van Wier, W.J.Chng, R.P.Ketterling, M.A.Gertz, K.Henderson, P.R.Greipp, A.Dispenzieri, M.Q.Lacy, S.V.Rajkumar, P.L.Bergsagel, A.K.Stewart, and R.Fonseca (2008).
Genetic aberrations and survival in plasma cell leukemia.
  Leukemia, 22, 1044-1052.  
18189286 R.Gabizon, M.Mor, M.M.Rosenberg, L.Britan, Z.Hayouka, M.Kotler, D.E.Shalev, and A.Friedler (2008).
Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat.
  Biopolymers, 90, 105-116.  
19440517 S.Donzelli, F.Biagioni, F.Fausti, S.Strano, G.Fontemaggi, and G.Blandino (2008).
Oncogenomic Approaches in Exploring Gain of Function of Mutant p53.
  Curr Genomics, 9, 200-207.  
18026140 S.K.Balakrishnan, and D.S.Gross (2008).
The tumor suppressor p53 associates with gene coding regions and co-traverses with elongating RNA polymerase II in an in vivo model.
  Oncogene, 27, 2661-2672.  
18676979 S.Patel, R.George, F.Autore, F.Fraternali, J.E.Ladbury, and P.V.Nikolova (2008).
Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax.
  Nucleic Acids Res, 36, 5139-5151.  
18199664 S.Rigacci, M.Bucciantini, A.Relini, A.Pesce, A.Gliozzi, A.Berti, and M.Stefani (2008).
The (1-63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies.
  Biophys J, 94, 3635-3646.  
18431400 T.Riley, E.Sontag, P.Chen, and A.Levine (2008).
Transcriptional control of human p53-regulated genes.
  Nat Rev Mol Cell Biol, 9, 402-412.  
17968669 W.Duan, L.Gao, D.Jin, G.A.Otterson, and M.A.Villalona-Calero (2008).
Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice.
  Transgenic Res, 17, 355-366.  
18461991 Y.Pan, and R.Nussinov (2008).
p53-Induced DNA bending: the interplay between p53-DNA and p53-p53 interactions.
  J Phys Chem B, 112, 6716-6724.  
18038118 Z.Guo, M.H.Tsai, Y.H.Shiao, L.H.Chen, M.L.Wei, X.Lv, D.Gius, J.B.Little, J.B.Mitchell, and E.Y.Chuang (2008).
DNA (cytosine-5)-methyltransferase 1 as a mediator of mutant p53-determined p16(ink4A) down-regulation.
  J Biomed Sci, 15, 163-168.  
17713798 A.Gieldon, M.Mori, and R.Del Conte (2007).
Theoretical study on binding of S100B protein.
  J Mol Model, 13, 1123-1131.  
17929268 A.Prowald, M.V.Cronauer, C.von Klot, T.Eilers, L.Rinnab, T.Herrmann, K.D.Spindler, M.Montenarh, U.Jonas, and M.Burchardt (2007).
Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53.
  Prostate, 67, 1751-1760.  
17986463 B.Ma, and A.J.Levine (2007).
Probing potential binding modes of the p53 tetramer to DNA based on the symmetries encoded in p53 response elements.
  Nucleic Acids Res, 35, 7733-7747.  
17439973 B.Ma, Y.Pan, J.Zheng, A.J.Levine, and R.Nussinov (2007).
Sequence analysis of p53 response-elements suggests multiple binding modes of the p53 tetramer to DNA targets.
  Nucleic Acids Res, 35, 2986-3001.  
17555331 C.S.Velu, S.K.Niture, C.E.Doneanu, N.Pattabiraman, and K.S.Srivenugopal (2007).
Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress.
  Biochemistry, 46, 7765-7780.  
17401428 D.Menendez, A.Inga, J.J.Jordan, and M.A.Resnick (2007).
Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson.
  Oncogene, 26, 2191-2201.  
17401427 E.Kim, and W.Deppert (2007).
Interactions of mutant p53 with DNA: guilt by association.
  Oncogene, 26, 2185-2190.  
17903248 E.Villiard, H.Brinkmann, O.Moiseeva, F.A.Mallette, G.Ferbeyre, and S.Roy (2007).
Urodele p53 tolerates amino acid changes found in p53 variants linked to human cancer.
  BMC Evol Biol, 7, 180.  
17130840 F.Mayelzadeh, and J.D.Martinez (2007).
DNA binding and selective gene induction by different forms of the p53 protein.
  Oncogene, 26, 2955-2963.  
17671971 G.P.Zambetti (2007).
The p53 mutation "gradient effect" and its clinical implications.
  J Cell Physiol, 213, 370-373.  
17609875 H.Kamata, S.Mitani, M.Fujiwara, N.Aoki, S.Okada, and S.Mori (2007).
Mutation of the p53 tumour suppressor gene and overexpression of its protein in 62 Japanese non-Hodgkin's lymphomas.
  Clin Exp Med, 7, 39-46.  
17347683 H.S.Bell, C.Dufes, J.O'Prey, D.Crighton, D.Bergamaschi, X.Lu, A.G.Schätzlein, K.H.Vousden, and K.M.Ryan (2007).
A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo.
  J Clin Invest, 117, 1008-1018.  
17620598 H.Tidow, R.Melero, E.Mylonas, S.M.Freund, J.G.Grossmann, J.M.Carazo, D.I.Svergun, M.Valle, and A.R.Fersht (2007).
Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex.
  Proc Natl Acad Sci U S A, 104, 12324-12329.  
17391014 H.Xie, S.Vucetic, L.M.Iakoucheva, C.J.Oldfield, A.K.Dunker, V.N.Uversky, and Z.Obradovic (2007).
Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions.
  J Proteome Res, 6, 1882-1898.  
17393459 I.N.Kasampalidis, I.Pitas, and K.Lyroudia (2007).
Conservation of metal-coordinating residues.
  Proteins, 68, 123-130.  
17914225 J.D.Wright, and C.Lim (2007).
Mechanism of DNA-binding loss upon single-point mutation in p53.
  J Biosci, 32, 827-839.  
18025460 K.E.Augustyn, E.J.Merino, and J.K.Barton (2007).
A role for DNA-mediated charge transport in regulating p53: Oxidation of the DNA-bound protein from a distance.
  Proc Natl Acad Sci U S A, 104, 18907-18912.  
17881637 K.H.Young, D.D.Weisenburger, B.J.Dave, L.Smith, W.Sanger, J.Iqbal, E.Campo, J.Delabie, R.D.Gascoyne, G.Ott, L.Rimsza, H.K.Müller-Hermelink, E.S.Jaffe, A.Rosenwald, L.M.Staudt, W.C.Chan, and T.C.Greiner (2007).
Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.
  Blood, 110, 4396-4405.  
17285122 K.Kaneko, A.Katagiri, K.Konishi, T.Kurahashi, H.Ito, Y.Kumekawa, T.Yamamoto, T.Muramoto, Y.Kubota, H.Nozawa, R.Makino, M.Kushima, and M.Imawari (2007).
Study of p53 gene alteration as a biomarker to evaluate the malignant risk of Lugol-unstained lesion with non-dysplasia in the oesophagus.
  Br J Cancer, 96, 492-498.  
17417775 K.Otsuka, S.Kato, Y.Kakudo, S.Mashiko, H.Shibata, and C.Ishioka (2007).
The screening of the second-site suppressor mutations of the common p53 mutants.
  Int J Cancer, 121, 559-566.  
17318340 L.P.van Hest, M.W.Ruijs, A.Wagner, C.A.van der Meer, S.Verhoef, L.J.van't Veer, and H.Meijers-Heijboer (2007).
Two TP53 germline mutations in a classical Li-Fraumeni syndrome family.
  Fam Cancer, 6, 311-316.  
18094376 M.L.Poeta, J.Manola, M.A.Goldwasser, A.Forastiere, N.Benoit, J.A.Califano, J.A.Ridge, J.Goodwin, D.Kenady, J.Saunders, W.Westra, D.Sidransky, and W.M.Koch (2007).
TP53 mutations and survival in squamous-cell carcinoma of the head and neck.
  N Engl J Med, 357, 2552-2561.  
17170001 M.Lokshin, Y.Li, C.Gaiddon, and C.Prives (2007).
p53 and p73 display common and distinct requirements for sequence specific binding to DNA.
  Nucleic Acids Res, 35, 340-352.  
17276395 M.Osada, H.L.Park, M.J.Park, J.W.Liu, G.Wu, B.Trink, and D.Sidransky (2007).
A p53-type response element in the GDF15 promoter confers high specificity for p53 activation.
  Biochem Biophys Res Commun, 354, 913-918.  
18282133 P.M.Chumakov (2007).
Versatile functions of p53 protein in multicellular organisms.
  Biochemistry (Mosc), 72, 1399-1421.  
17824689 Q.Lu, Y.H.Tan, and R.Luo (2007).
Molecular dynamics simulations of p53 DNA-binding domain.
  J Phys Chem B, 111, 11538-11545.  
17646286 S.A.Danziger, J.Zeng, Y.Wang, R.K.Brachmann, and R.H.Lathrop (2007).
Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants.
  Bioinformatics, 23, i104-i114.  
17123310 S.Strano, S.Dell'Orso, A.M.Mongiovi, O.Monti, E.Lapi, S.Di Agostino, G.Fontemaggi, and G.Blandino (2007).
Mutant p53 proteins: between loss and gain of function.
  Head Neck, 29, 488-496.  
17703463 V.De Grandis, A.R.Bizzarri, and S.Cannistraro (2007).
Docking study and free energy simulation of the complex between p53 DNA-binding domain and azurin.
  J Mol Recognit, 20, 215-226.  
  18007958 W.B.Bowne, J.Michl, M.H.Bluth, M.E.Zenilman, and M.R.Pincus (2007).
Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer.
  Cancer Ther, 5, 331-344.  
17327663 Y.Wang, A.Rosengarth, and H.Luecke (2007).
Structure of the human p53 core domain in the absence of DNA.
  Acta Crystallogr D Biol Crystallogr, 63, 276-281.
PDB code: 2ocj
17640907 Z.Shakked (2007).
Quaternary structure of p53: the light at the end of the tunnel.
  Proc Natl Acad Sci U S A, 104, 12231-12232.  
17015838 A.C.Joerger, H.C.Ang, and A.R.Fersht (2006).
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs.
  Proc Natl Acad Sci U S A, 103, 15056-15061.
PDB codes: 2j1w 2j1x 2j1y 2j1z 2j20 2j21
17065008 A.Feuerborn, C.Möritz, F.Von Bonin, M.Dobbelstein, L.Trümper, B.Stürzenhofecker, and D.Kube (2006).
Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma.
  Leuk Lymphoma, 47, 1932-1940.  
16601005 A.L.Cuff, R.W.Janes, and A.C.Martin (2006).
Analysing the ability to retain sidechain hydrogen-bonds in mutant proteins.
  Bioinformatics, 22, 1464-1470.  
17053786 A.L.Okorokov, M.B.Sherman, C.Plisson, V.Grinkevich, K.Sigmundsson, G.Selivanova, J.Milner, and E.V.Orlova (2006).
The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity.
  EMBO J, 25, 5191-5200.  
15965904 A.Russo, S.Corsale, V.Agnese, M.Macaluso, S.Cascio, L.Bruno, E.Surmacz, G.Dardanoni, M.R.Valerio, S.Vieni, S.Restivo, F.Fulfaro, R.M.Tomasino, N.Gebbia, and V.Bazan (2006).
TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma.
  J Cell Physiol, 206, 181-188.  
16690321 B.P.Bouchet, C.C.de Fromentel, A.Puisieux, and C.M.Galmarini (2006).
p53 as a target for anti-cancer drug development.
  Crit Rev Oncol Hematol, 58, 190-207.  
16447252 C.Augello, V.Gregorio, V.Bazan, P.Cammareri, V.Agnese, S.Cascio, S.Corsale, V.Calò, A.Gullo, R.Passantino, G.Gargano, L.Bruno, G.Rinaldi, V.Morello, A.Gerbino, R.M.Tomasino, M.Macaluso, E.Surmacz, and A.Russo (2006).
TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas.
  J Cell Physiol, 207, 654-659.  
16461914 D.B.Veprintsev, S.M.Freund, A.Andreeva, S.E.Rutledge, H.Tidow, J.M.Cañadillas, C.M.Blair, and A.R.Fersht (2006).
Core domain interactions in full-length p53 in solution.
  Proc Natl Acad Sci U S A, 103, 2115-2119.  
16278824 D.Hamroun, S.Kato, C.Ishioka, M.Claustres, C.Béroud, and T.Soussi (2006).
The UMD TP53 database and website: update and revisions.
  Hum Mutat, 27, 14-20.  
16508005 D.Menendez, A.Inga, and M.A.Resnick (2006).
The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes.
  Mol Cell Biol, 26, 2297-2308.  
16165254 D.Uberti, C.Lanni, T.Carsana, S.Francisconi, C.Missale, M.Racchi, S.Govoni, and M.Memo (2006).
Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients.
  Neurobiol Aging, 27, 1193-1201.  
16543936 E.Kim, and W.Deppert (2006).
The versatile interactions of p53 with DNA: when flexibility serves specificity.
  Cell Death Differ, 13, 885-889.  
16395672 E.Mathe, M.Olivier, S.Kato, C.Ishioka, I.Vaisman, and P.Hainaut (2006).
Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations.
  Hum Mutat, 27, 163-172.  
16522644 E.Mathe, M.Olivier, S.Kato, C.Ishioka, P.Hainaut, and S.V.Tavtigian (2006).
Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods.
  Nucleic Acids Res, 34, 1317-1325.  
16981429 H.Iijima, N.Kasai, H.Chiku, S.Murakami, F.Sugawara, K.Sakaguchi, H.Yoshida, and Y.Mizushina (2006).
The inhibitory action of long-chain fatty acids on the DNA binding activity of p53.
  Lipids, 41, 521-527.  
16981908 H.Pivonková, P.Pecinka, P.Cesková, and M.Fojta (2006).
DNA modification with cisplatin affects sequence-specific DNA binding of p53 and p73 proteins in a target site-dependent manner.
  FEBS J, 273, 4693-4706.  
20141510 J.Deng, R.Dayam, and N.Neamati (2006).
Patented small molecule inhibitors of p53-MDM2 interaction.
  Expert Opin Ther Pat, 16, 165-188.  
16461916 J.M.Cañadillas, H.Tidow, S.M.Freund, T.J.Rutherford, H.C.Ang, and A.R.Fersht (2006).
Solution structure of p53 core domain: structural basis for its instability.
  Proc Natl Acad Sci U S A, 103, 2109-2114.
PDB code: 2fej
16385586 J.M.Kraniak, J.Abrams, J.E.Nowak, and M.A.Tainsky (2006).
Antioxidant agents transiently inhibit aneuploidy progression in Li-Fraumeni cell strains.
  Mol Carcinog, 45, 141-156.  
16543939 K.L.Harms, and X.Chen (2006).
The functional domains in p53 family proteins exhibit both common and distinct properties.
  Cell Death Differ, 13, 890-897.  
16393249 K.Leng, S.Schlien, and F.X.Bosch (2006).
Refined characterization of head and neck squamous cell carcinomas expressing a seemingly wild-type p53 protein.
  J Oral Pathol Med, 35, 19-24.  
16983711 L.Römer, C.Klein, A.Dehner, H.Kessler, and J.Buchner (2006).
p53--a natural cancer killer: structural insights and therapeutic concepts.
  Angew Chem Int Ed Engl, 45, 6440-6460.  
16676359 L.Resnick-Silverman, and J.J.Manfredi (2006).
Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy.
  J Cell Biochem, 99, 679-689.  
16607663 M.J.Schmid, K.Manthiram, S.M.Grayson, J.C.Willson, J.E.Meiring, K.M.Bell, A.D.Ellington, and C.G.Willson (2006).
Feature multiplexing--improving the efficiency of microarray devices.
  Angew Chem Int Ed Engl, 45, 3338-3341.  
16793544 M.Kitayner, H.Rozenberg, N.Kessler, D.Rabinovich, L.Shaulov, T.E.Haran, and Z.Shakked (2006).
Structural basis of DNA recognition by p53 tetramers.
  Mol Cell, 22, 741-753.
PDB codes: 2ac0 2ady 2ahi 2ata
16821145 M.Matsumoto, M.Furihata, and Y.Ohtsuki (2006).
Posttranslational phosphorylation of mutant p53 protein in tumor development.
  Med Mol Morphol, 39, 79-87.  
16570054 M.Tang, G.M.Wahl, and M.Nistér (2006).
Explaining the biological activity of transactivation-deficient p53 variants.
  Nat Genet, 38, 395.  
16541312 M.Wasielewski, F.Elstrodt, J.G.Klijn, E.M.Berns, and M.Schutte (2006).
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
  Breast Cancer Res Treat, 99, 97.  
19003072 N.Arden, and M.J.Betenbaugh (2006).
Regulating apoptosis in mammalian cell cultures.
  Cytotechnology, 50, 77-92.  
17014330 N.Banerji, and S.Kanjilal (2006).
Somatic alterations of the p53 tumor suppressor gene in vaccine-associated feline sarcoma.
  Am J Vet Res, 67, 1766-1772.  
16807229 N.Kantarci, P.Doruker, and T.Haliloglu (2006).
Cooperative fluctuations point to the dimerization interface of p53 core domain.
  Biophys J, 91, 421-432.  
16575405 O.Laptenko, and C.Prives (2006).
Transcriptional regulation by p53: one protein, many possibilities.
  Cell Death Differ, 13, 951-961.  
16603489 P.Hinow, C.E.Rogers, C.E.Barbieri, J.A.Pietenpol, A.K.Kenworthy, and E.DiBenedetto (2006).
The DNA binding activity of p53 displays reaction-diffusion kinetics.
  Biophys J, 91, 330-342.  
16962967 P.Prabakaran, J.G.Siebers, S.Ahmad, M.M.Gromiha, M.G.Singarayan, and A.Sarai (2006).
Classification of protein-DNA complexes based on structural descriptors.
  Structure, 14, 1355-1367.  
17189187 S.M.Sykes, H.S.Mellert, M.A.Holbert, K.Li, R.Marmorstein, W.S.Lane, and S.B.McMahon (2006).
Acetylation of the p53 DNA-binding domain regulates apoptosis induction.
  Mol Cell, 24, 841-851.  
16641528 S.P.Hussain, and C.C.Harris (2006).
p53 biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis.
  J Nippon Med Sch, 73, 54-64.  
16980371 S.Zhong, J.M.Moix, S.Quirk, and R.Hernandez (2006).
Dihedral-angle information entropy as a gauge of secondary structure propensity.
  Biophys J, 91, 4014-4023.  
16689923 T.K.Chaudhuri, and S.Paul (2006).
Protein-misfolding diseases and chaperone-based therapeutic approaches.
  FEBS J, 273, 1331-1349.  
17139084 W.C.Ho, C.Luo, K.Zhao, X.Chai, M.X.Fitzgerald, and R.Marmorstein (2006).
High-resolution structure of the p53 core domain: implications for binding small-molecule stabilizing compounds.
  Acta Crystallogr D Biol Crystallogr, 62, 1484-1493.
PDB codes: 2ioi 2iom 2ioo
16528528 W.Ichikawa, A.Ooyama, E.Toda, Y.Sugimoto, T.Oka, T.Takahashi, M.Shimizu, Y.Sasaki, and R.Hirayama (2006).
Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
  Cancer Chemother Pharmacol, 58, 794-801.  
16951253 W.Lilyestrom, M.G.Klein, R.Zhang, A.Joachimiak, and X.S.Chen (2006).
Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor.
  Genes Dev, 20, 2373-2382.
PDB code: 2h1l
16987000 W.Maret (2006).
Zinc coordination environments in proteins as redox sensors and signal transducers.
  Antioxid Redox Signal, 8, 1419-1441.  
16917930 Y.L.Yip, V.Zoete, H.Scheib, and O.Michielin (2006).
Structural assessment of single amino acid mutations: application to TP53 function.
  Hum Mutat, 27, 926-937.  
16827804 Y.Nakamura, M.Futamura, H.Kamino, K.Yoshida, Y.Nakamura, and H.Arakawa (2006).
Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis.
  Cancer Sci, 97, 633-641.  
17189186 Y.Tang, J.Luo, W.Zhang, and W.Gu (2006).
Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis.
  Mol Cell, 24, 827-839.  
17156454 Y.Taniguchi, S.Takeda, M.Furutani-Seiki, Y.Kamei, T.Todo, T.Sasado, T.Deguchi, H.Kondoh, J.Mudde, M.Yamazoe, M.Hidaka, H.Mitani, A.Toyoda, Y.Sakaki, R.H.Plasterk, and E.Cuppen (2006).
Generation of medaka gene knockout models by target-selected mutagenesis.
  Genome Biol, 7, R116.  
16266265 A.A.Morgunkova (2005).
The p53 gene family: control of cell proliferation and developmental programs.
  Biochemistry (Mosc), 70, 955-971.  
16035029 A.Dehner, C.Klein, S.Hansen, L.Müller, J.Buchner, M.Schwaiger, and H.Kessler (2005).
Cooperative binding of p53 to DNA: regulation by protein-protein interactions through a double salt bridge.
  Angew Chem Int Ed Engl, 44, 5247-5251.  
16138303 A.Dehner, and H.Kessler (2005).
Diffusion NMR spectroscopy: folding and aggregation of domains in p53.
  Chembiochem, 6, 1550-1565.  
15837201 A.Friedler, D.B.Veprintsev, S.M.Freund, K.I.von Glos, and A.R.Fersht (2005).
Modulation of binding of DNA to the C-terminal domain of p53 by acetylation.
  Structure, 13, 629-636.  
16204849 B.Ma, Y.Pan, K.Gunasekaran, O.Keskin, R.B.Venkataraghavan, A.J.Levine, and R.Nussinov (2005).
The contribution of the Trp/Met/Phe residues to physical interactions of p53 with cellular proteins.
  Phys Biol, 2, S56-S66.  
15738397 B.Ma, Y.Pan, K.Gunasekaran, R.B.Venkataraghavan, A.J.Levine, and R.Nussinov (2005).
Comparison of the protein-protein interfaces in the p53-DNA crystal structures: towards elucidation of the biological interface.
  Proc Natl Acad Sci U S A, 102, 3988-3993.  
15868375 C.Fimognari, L.Sangiorgi, S.Capponcelli, M.Nüsse, S.Fontanesi, F.Berti, S.Soddu, G.Cantelli-Forti, and P.Hrelia (2005).
A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug.
  Invest New Drugs, 23, 195-203.  
16168367 C.Prives, and J.J.Manfredi (2005).
The continuing saga of p53--more sleepless nights ahead.
  Mol Cell, 19, 719-721.  
15499621 C.Ryk, P.Berggren, R.Kumar, K.Hemminki, P.Larsson, G.Steineck, B.Lambert, and S.M.Hou (2005).
Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutational spectrum in bladder tumours.
  Int J Cancer, 113, 761-768.  
15969767 D.H.Dreyfus, M.Nagasawa, E.W.Gelfand, and L.Y.Ghoda (2005).
Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors.
  BMC Immunol, 6, 12.  
16869788 D.P.Lane (2005).
Exploiting the p53 pathway for the diagnosis and therapy of human cancer.
  Cold Spring Harb Symp Quant Biol, 70, 489-497.  
15965030 E.A.Stone, and A.Sidow (2005).
Physicochemical constraint violation by missense substitutions mediates impairment of protein function and disease severity.
  Genome Res, 15, 978-986.  
16234232 E.Bochkareva, L.Kaustov, A.Ayed, G.S.Yi, Y.Lu, A.Pineda-Lucena, J.C.Liao, A.L.Okorokov, J.Milner, C.H.Arrowsmith, and A.Bochkarev (2005).
Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A.
  Proc Natl Acad Sci U S A, 102, 15412-15417.
PDB codes: 2b29 2b3g
15643668 G.Lozano, and G.P.Zambetti (2005).
What have animal models taught us about the p53 pathway?
  J Pathol, 205, 206-220.  
16173033 I.P.Gorlov, O.Y.Gorlova, and C.I.Amos (2005).
Predicting the oncogenicity of missense mutations reported in the International Agency for Cancer Research (IARC) mutation database on p53.
  Hum Mutat, 26, 446-454.  
15875732 J.Shaminie, S.C.Peh, and J.Tan (2005).
p53 alterations in sequential biopsies of Asian follicular lymphoma: a study of immunohistochemical staining pattern and gene mutations by PCR-SSCP in paraffin-embedded tissues.
  Pathology, 37, 39-44.  
15750621 K.Mann, and P.Hainaut (2005).
Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53.
  Oncogene, 24, 3964-3975.  
16096528 M.E.Cavalier, M.M.Davis, and J.M.Croop (2005).
Germline p53 mutation presenting as synchronous tumors.
  J Pediatr Hematol Oncol, 27, 441-443.  
16260623 M.J.Scian, K.E.Stagliano, M.A.Anderson, S.Hassan, M.Bowman, M.F.Miles, S.P.Deb, and S.Deb (2005).
Tumor-derived p53 mutants induce NF-kappaB2 gene expression.
  Mol Cell Biol, 25, 10097-10110.  
15824059 P.D.Vise, B.Baral, A.J.Latos, and G.W.Daughdrill (2005).
NMR chemical shift and relaxation measurements provide evidence for the coupled folding and binding of the p53 transactivation domain.
  Nucleic Acids Res, 33, 2061-2077.  
16059916 R.Sarimov, E.Markova, F.Johansson, D.Jenssen, and I.Belyaev (2005).
Exposure to ELF magnetic field tuned to Zn inhibits growth of cancer cells.
  Bioelectromagnetics, 26, 631-638.  
15973455 R.Schmitz, C.Renné, R.Rosenquist, M.Tinguely, V.Distler, F.Menestrina, M.Lestani, T.Stankovic, B.Austen, A.Bräuninger, M.L.Hansmann, and R.Küppers (2005).
Insights into the multistep transformation process of lymphomas: IgH-associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin's and non-Hodgkin's lymphomas.
  Leukemia, 19, 1452-1458.  
15630097 S.Berghmans, R.D.Murphey, E.Wienholds, D.Neuberg, J.L.Kutok, C.D.Fletcher, J.P.Morris, T.X.Liu, S.Schulte-Merker, J.P.Kanki, R.Plasterk, L.I.Zon, and A.T.Look (2005).
tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors.
  Proc Natl Acad Sci U S A, 102, 407-412.  
15977174 S.Capponcelli, E.Pedrini, M.A.Cerone, V.Corti, S.Fontanesi, M.Alessio, A.Bachi, S.Soddu, D.Ribatti, P.Picci, L.J.Helman, G.Cantelli-Forti, and L.Sangiorgi (2005).
Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation.
  Hum Mutat, 26, 94.  
15939931 S.J.Oh, J.Ju, B.C.Kim, E.Ko, B.J.Hong, J.G.Park, J.W.Park, and K.Y.Choi (2005).
DNA microarrays on a dendron-modified surface improve significantly the detection of single nucleotide variations in the p53 gene.
  Nucleic Acids Res, 33, e90.